Korean J Pathol.  2014 Apr;48(2):108-116.

IMP3, a Promising Prognostic Marker in Clear Cell Renal Cell Carcinoma

Affiliations
  • 1Department of Pathology, Keimyung University School of Medicine, Daegu, Korea. msc@dsmc.or.kr

Abstract

BACKGROUND
Insulin-like growth factor II mRNA-binding protein 3 (IMP3) has been reported as a prognostic biomarker in various cancers. To validate IMP3 as a prognostic biomarker in renal cell carcinoma (RCC), we investigated the expression of IMP3, p53, and Ki-67, and their associations with clinicopathologic outcomes.
METHODS
We studied 148 clear cell RCCs (CCRCCs) from patients who underwent radical nephrectomy. The expression levels of IMP3, p53, and Ki-67 were assessed by immunohistochemical staining and the clinical and pathologic parameters were retrospectively reviewed.
RESULTS
Twenty-nine percent of CCRCCs expressed IMP3. Forty-one percent of IMP3-immunopositive tumors developed metastases, while only 11.4% of IMP3-negative tumors developed metastases (p<.001). A Kaplan-Meier curve showed that patients with IMP3-immunopositive tumors had lower metastasis-free survival and cancer-specific survival than did those with IMP3-immunonegative tumors (p<.001 and p<.001, respectively). Expression of high Ki-67 proliferation index was also associated with a higher metastatic rate. In the multivariate Cox regression analysis, pT stage and IMP3-positivity were independently associated with disease-specific survival.
CONCLUSIONS
IMP3 is an independent prognostic biomarker for patients with CCRCC to predict metastasis and poor outcome.

Keyword

Carcinoma, renal cell; IMP3; Tumor suppressor protein p53; Ki-67; Neoplasm metastasis

MeSH Terms

Carcinoma, Renal Cell*
Humans
Insulin-Like Growth Factor II
Neoplasm Metastasis
Nephrectomy
Retrospective Studies
Tumor Suppressor Protein p53
Insulin-Like Growth Factor II
Tumor Suppressor Protein p53
Full Text Links
  • KJP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr